Biofrontera announces conference call to be held on November 12, 2020 to discuss Q3 2020 financial results
November 02, 2020 08:00 ET
|
Biofrontera AG
Leverkusen, Germany, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its...
Biofrontera implements comprehensive measures to reduce costs during COVID-19 pandemic
March 20, 2020 04:15 ET
|
Biofrontera AG
Leverkusen, Germany, March 20, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announced today that...
Biofrontera announces 1-year follow-up results for its phase III study of photodynamic therapy for actinic keratosis on the extremities and trunk/neck
January 14, 2020 00:30 ET
|
Biofrontera AG
Leverkusen, Germany, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today announced...
Results of the voluntary partial tender offers
July 24, 2019 06:30 ET
|
Biofrontera AG
Leverkusen, Germany, July 24, 2019 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, informs about the...